Literature DB >> 7831768

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.

T Sasagawa1, P Pushko, G Steers, S E Gschmeissner, M A Hajibagheri, J Finch, L Crawford, M Tommasino.   

Abstract

We have synthesized capsid proteins of human papillomavirus types 6 (HPV 6) and 16 (HPV 16) in fission yeast Schizosaccharomyces pombe and produced virus-like particles (VLP). The capsid proteins were localized in the nucleus by indirect immunofluorescence and cell fractionation analyses. The VLP were produced in both yeast clones synthesizing L1 alone and L/L2 and purified by sulfato-cellulofine chromatography. Electron microscopic examination showed that these VLP were similar in structure to native HPV particles. Two HPV 16 L1 variants (16 B27L1 and 16 T3L1), isolated from benign cervical samples, produced many more (68- and 14-fold) VLP than the prototype L1 (16 PL1) derived from cervical carcinoma. Coexpression of the HPV 6 L2 protein with 6 L1 and 16 B27L1 proteins increased the production level of the VLP four- and twofold, respectively. The L2 was not detected in the VLP purified with sulfato-cellulofine column, although the L2 was purified in the same fraction containing HPV 6 and 16 B27-VLP by size-fractionation using Sepharose column. Interaction between 6 L2 and 6/16 L1 proteins was not detected by the coimmunoprecipitation assays with either L1 or L2 antibodies. These results suggest that the L2 is not incorporated into the VLP synthesized in yeast.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7831768     DOI: 10.1016/s0042-6822(95)80027-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  47 in total

1.  Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells.

Authors:  Karina Araujo Aires; Aurora Marques Cianciarullo; Sylvia Mendes Carneiro; Luisa Lina Villa; Enrique Boccardo; Gaspar Pérez-Martinez; Isabel Perez-Arellano; Maria Leonor Sarno Oliveira; Paulo Lee Ho
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

2.  Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo.

Authors:  Kong-Nan Zhao; WenYi Gu; Ning Xia Fang; Nicholas A Saunders; Ian H Frazer
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

3.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

5.  LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus.

Authors:  Jong-Eun Lee; Hyunjung Jade Lim
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

6.  Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b.

Authors:  M A Ozbun; C Meyers
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

8.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

9.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.

Authors:  Archana Monie; Chien-Fu Hung; Richard Roden; T-C Wu
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.